VT 301
Alternative Names: VT-301; VT301 - VT BioLatest Information Update: 16 Jan 2024
At a glance
- Originator VT BIO
- Class Antidementias; Regulatory T lymphocyte cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 16 Jan 2024 VT 301 is still in phase I trial in Alzheimer's disease in South Korea (Parenteral) (VT Bio pipeline, January 2024)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In adults) in South Korea (Parenteral, Injection)
- 01 Nov 2020 Phase-I clinical trials in Alzheimer's disease (In adults, In the elderly) in South Korea (Parenteral) (NCT05016427)